Abbott Laboratories (ABT)
Abbott looks like a steadier diversified healthcare hold than a hard-rating opportunity, with the current valuation spread still moderate rather than wide.
This page preserves the published note at the report date shown below. For the live workspace with the latest daily scheduled quote, filing, fundamentals, and refreshed model output, return to the company page.
Current workspace reference
Kept here as reference beside the published report: the current workspace now shows a Buy signal with low confidence as shares are currently being evaluated against an older daily scheduled quote of $88 versus $102 fair value, implying +15.2 upside.
Current workspace signal
Buy
Confidence
Low
Stale scheduled quote
$88
Fair value
$102
+15.2 upside
Reference freshness
Price basis
Stale scheduled quote
Latest daily scheduled quote is past the freshness window. Daily scheduled refresh as of May 21, 2026, 6:52 AM UTC. Fresh through May 22, 2026, 6:52 AM UTC.
Filing reference
SD filed May 27, 2026
Filing refreshed Jun 6, 2026, 6:27 AM UTC. Fresh through Jun 6, 2026, 6:27 PM UTC.
Fundamentals reference
Live SEC companyfacts currently cover revenue, operating margin, free cash flow, and net cash / net debt. Reporting period end 2025-12-31.
Fundamentals refreshed 6 Jun 2026, 06:27 UTC. Fresh through 6 Jun 2026, 18:27 UTC.
Model vs published view
Current model signal differs from the latest published analyst rating.
Thesis scorecard
Growth
ModerateGrowth is diversified and durable, though not unusually fast.
Profitability
ModerateMargins are solid, though not at the level of the best software or payment franchises.
Balance sheet
ModerateLeverage is manageable against the cash-flow profile.
Valuation
ModerateThe current multiple is reasonable, but the spread to fair value is still contained.
Execution / Resilience
StrongDiversification across devices, diagnostics, and nutrition supports resilience.
Bull / Base / Bear scenarios
Bull case
$110
Normalized support: Growth, margin, and cash-flow trends are mixed versus the upside case.
Base case
$102
Normalized support: Current margin, cash-generation, and balance-sheet profile are mixed.
Bear case
$89
Downside protection: Cash generation and balance-sheet support are mixed in the bear case.
Base-case assumptions
These are the published base-case assumptions behind the note. They are reasoned valuation inputs at the report date, not reported facts.
Revenue CAGR (5Y)
5.0%
+/- 1.0% => +/-$4/sh
Why this level: This is AnalystScope's base-case growth assumption, not a guarantee. It sits below the latest FY model-base revenue pace (2025.0%), so the model does not extend current strength too far into the outer years. Current company context: A diversified healthcare portfolio reduces dependence on any one procedure or product cycle.
Terminal Growth
2.5%
+/- 0.5% => +/-$3/sh
Why this level: This is AnalystScope's mature long-run growth assumption, not a perpetual hypergrowth claim. At 2.5%, it sits well below the 5.0% five-year revenue CAGR, so the model steps down from the explicit forecast period to a steadier long-run pace. For Abbott Laboratories, that means a durable franchise can keep compounding after year five without assuming today's faster growth profile lasts indefinitely.
WACC
8.0%
+/- 0.5% => -$4/sh
Why this level: This is AnalystScope's base-case cost-of-capital judgment, not a precise CAPM output. It reflects the current rates backdrop, equity risk premium, and the company's balance-sheet posture. Balance sheet remains manageable against diversified healthcare cash generation
Operating Margin (Year 5)
17.8%
+/- 100 bps => +/-$3/sh
Why this level: This is AnalystScope's base-case margin view, not a promise of straight-line expansion. It keeps year-five margins close to today's model-base operating margin (16.9%), which implies the current margin structure is broadly durable. Margin input keeps the base on durable diversified-healthcare economics rather than temporary mix or supply-chain relief.
How to read the assumptions and sensitivities
These are base-case assumptions used to estimate fair value. They are reasonable model inputs, not reported facts.
Each sensitivity line shows the estimated fair-value-per-share change from a small move in that one input while the other inputs stay fixed.
bps means basis points. 100 bps equals 1.00 percentage point.
WACC sensitivity moves in the opposite direction because a higher discount rate lowers present value, while a lower discount rate raises it.
Model base vs reported fundamentals
Side-by-side view of the latest live reported fundamentals versus the current AnalystScope model base used in public valuation and thesis work.
Reported numbers show the latest company print. Model base is the comparable operating base AnalystScope uses for valuation work, which can include standardization, conservative balance-sheet treatment, working-capital cleanup, and through-cycle adjustments when current reported figures do not look durable.
Reported fundamentals source
SEC XBRL companyfacts API
Live SEC companyfacts currently cover revenue, operating margin, free cash flow, and net cash / net debt. Reporting period end 2025-12-31.
Fundamentals refreshed 6 Jun 2026, 06:27 UTC. Fresh through 6 Jun 2026, 18:27 UTC.
Model-base impact on the thesis
For Abbott, the model base is intended to reflect diversified healthcare economics through product-cycle and procedure noise rather than a single period's operating mix.
| Metric | Live reported | Status | Model base | Status |
|---|---|---|---|---|
| Revenue (TTM) | $44.3B | Live reported | $44.3B +5.5% YoY Adjustment: Model revenue smooths device, diagnostics, and nutrition timing rather than extrapolating any one procedure or respiratory season. | Model base |
| Operating Margin | 18.2% | Live reported | 16.9% +74 bps YoY Adjustment: Margin input keeps the base on durable diversified-healthcare economics rather than temporary mix or supply-chain relief. | Model base |
| FCF (TTM) | $7.4B | Live reported | $6.4B 14.4% margin Adjustment: FCF input adjusts for working-capital timing and keeps the cash-conversion base conservative. | Model base |
| Net Cash / (Debt) | ($27.2B) | Live reported | ($5.0B) Balance sheet remains manageable against diversified healthcare cash generation Adjustment: Balance-sheet treatment remains measured and does not assume all cash is freely distributable. | Model base |
Published investment view
The published report remains anchored to a Hold rating, with the latest note event recorded as New. The current workspace now evaluates the stock against $88 versus a base-case fair value of $102, implying +15.2 upside.
Fair value $102 vs. current $88 (+15.2 upside).
Confidence framing
Method agreement / dispersion
Valuation methods show a wider range from $93 to $110, which tempers conviction.
Margin strength
Operating margin is 16.9%, with +74 bps vs prior FY.
Balance sheet position
Balance sheet positioning is ($5.0B), with balance sheet remains manageable against diversified healthcare cash generation.
Key drivers
A diversified healthcare portfolio reduces dependence on any one procedure or product cycle.
Reasonable margin durability and cash conversion support downside protection.
The current valuation leaves some room for steady execution, but not enough to force a stronger rating.
Key risks
Procedure, diagnostics, or product-cycle softness could keep results below the current through-cycle base.
The setup is diversified, but that also limits the odds of a sharp near-term rerating.
If margin improvement stalls while the multiple holds, the upside case would stay constrained.
What would change our view
A wider discount to fair value would make the diversified-healthcare story more attractive.
Clearer evidence of durable device and diagnostics acceleration would improve conviction.
If growth softens while margins stay capped, the current Hold stance would be harder to defend.
Near-term catalysts
Device procedure commentary and diagnostics demand remain the clearest near-term signals.
Gross-margin mix and cash-conversion quality matter as much as any single revenue beat in this setup.
Any cleaner evidence of broad-based portfolio acceleration would improve the current valuation read-through.
What we are watching
Whether diversified portfolio growth remains balanced rather than dependent on one faster segment.
How durable current margin stability is as product mix shifts.
Whether free-cash-flow conversion remains strong enough to support the current fair-value range.
Report archive context
Archive metadata below keeps the published report context visible. Current workspace valuation and quote context stay secondary on this page.
How to read note event vs rating
Note event tells you what changed in the latest published note. Published rating shows the stance after that event.
Both were published Apr 10, 2026.
Report updated
Apr 10, 2026
Coverage status
Active coverage
Latest note event
New
Published Apr 10, 2026
Current published rating
Hold
Published Apr 10, 2026
Analyst note
Watching portfolio breadth, margin durability, and whether diversified healthcare resilience is translating into stronger fair-value support.
What changed in the report
Apr 10, 2026
Added to AnalystScope coverage
Impact: New Hold view on diversified healthcare durability
Apr 10, 2026
Kept valuation framing disciplined
Impact: Avoids overstating upside from a still-contained spread to fair value
Report timeline
Apr 10, 2026
Started coverage with a Hold view on diversified healthcare quality and a moderate spread to fair value.